🇺🇸 FDA
Patent

US 10799584

Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10799584 (Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K31/4745